Baseline patient, disease and prior treatment characteristics
| Characteristics | N = 41 |
|---|---|
| Median Age (Range) | 58 (33–82) |
| Gender | Male: 29 (71%) |
| Female: 12 (29%) | |
| ECOG PS | 0: 15 (40%) |
| 1: 18 (47%) | |
| 2: 5 (13%) | |
| Unknown: 3 | |
| Race | Caucasian: 27 (68%) |
| African American: 10 (25%) | |
| Hispanic: 3 (7%) | |
| Unknown: 1 | |
| Histology | Papillary: 16 (39%) |
| Unclassified: 14 (34%) | |
| Chromophobe: 5 (12%) | |
| Collecting Duct: 4 (10%) | |
| Translocation: 1 (2%) | |
| Mucinous Tubular and Spindle Cell Carcinoma (MTSCC): 1 (2%) | |
| Risk Group | MSKCC Criteria [15] |
| Favorable: 8 (21%) | |
| Intermediate: 25 (64%) | |
| Poor: 6 (15%) | |
| Unknown: 2 | |
| IMDC Criteria [16] | |
| Favorable: 10 (27%) | |
| Intermediate: 23 (62%) | |
| Poor: 4 (11%) | |
| Unknown: 4 | |
| Location of Metastases(more than 1 possible) | Retroperitoneal LNs: 26 (63%) |
| Lung: 22 (54%) | |
| Liver: 15 (37%) | |
| Bone: 11 (27%) | |
| Mediastinal LNs: 11 (27%) | |
| Supraclavicular LNs: 7 (17%) | |
| Mesenteric LNs: 5 (12%) | |
| Pelvic Mass: 4 (10%) | |
| Adrenal: 4 (10%) | |
| Omentum: 3 (7%) | |
| Pancreas, brain, contralateral kidney, soft tissue: 2 each (5%) | |
| Spleen, diaphragm, gallbladder, iliac LNs: 1 each (2%) | |
| Prior Nephrectomy | 29 (73%) |
| Number of Prior Systemic Therapies | 0: 3 (8%) |
| 1: 25 (62%) | |
| 2: 8 (20%) | |
| 3 or more: 4 (10%) | |
| Unknown: 1 | |
| Prior Therapies(more than 1 possible) | Sunitinib: 26 (63%) |
| Pazopanib: 11 (27%) | |
| Axitinib: 4 (10%) | |
| Everolimus: 4 (10%) | |
| Cabozantinib: 3 (7%) | |
| Gemcitabine/Cisplatin: 3 (7%) | |
| Carboplatin/Taxol: 1 (2%) | |
| Sorafenib: 1 (2%) | |
| Bevacizumab/Everolimus: 1 (2%) | |
| Prior Immunotherapy | Atezolizumab on trial: 1 (2%)Ipi/Nivo trial and J14186 HAR vaccine trial: 1 (2%) |
In some categories percentages do not add up to 100% due to rounding
Abbreviations: ECOG PS Eastern Cooperative Oncology Group Performance Status, MSKCC Memorial Sloan Kettering Cancer Center, IMDC International Metastatic Renal Cell Carcinoma Database Consortium, LNs Lymph Nodes